Skin Barrier Dysfunction, Antimicrobial Peptide Alterations, and Microbiome Changes in Solid Cancer Patients Treated with Epidermal Growth Factor Receptor Inhibitors
Dermatology · 05.06.2026 · 242 (4) · 457-470
DOI: 10.1159/000551797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology, online erschienen am 05.06.2026. Verfasst von Naraporn Somboonna und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Antimicrobial Peptides, Neoplasms, Skin, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Epidermal growth factor receptor inhibitors (EGFRIs) are targeted therapies for solid cancers. Their use is associated with cutaneous adverse events (cAEs). This study aimed to investigate cAEs and changes in skin biophysics reflecting the skin barrier function, alterations in antimicrobial peptides (AMPs), and the skin microbiome in patients undergoing treatment with EGFRIs.
Methods
A 2-year prospective cohort study was conducted involving patients receiving EGFRIs for solid cancers. cAEs and skin biophysical properties, including transepidermal water loss (TEWL), skin pH, elasticity, sebum, and pigmentation, were measured at baseline and follow-up visits up to 48 weeks. AMPs were assessed using a tape-stripping technique from the cheeks at months 0, 1, and 6, with protein assays and ELISA to determine the levels of human beta-defensin (hBD)-3 and ribonuclease (RNase)-7. Skin microbiome analysis was performed through 16S rRNA sequencing of cheek swabs collected at months 0, 1, and 6.
Results
Eighty-four patients were enrolled. The cumulative incidence of cAEs was 94.05%. Skin biophysical properties showed significantly increased TEWL and pH, decreased pigmentation, and no significant changes in elasticity and sebum. AMP analysis from 15 patients revealed significant reduction of RNase-7 levels after 6 months into EGFRIs, while hBD-3 level change was insignificant. A microbiome study from 18 patients showed statistically increased Corynebacterium kroppenstedtii at months 1 and 6, while Cutibacterium acnes, Corynebacterium aurimucosum, Staphylococcus epidermidis, and Staphylococcus aureus were not significantly different among groups.
Conclusion
Treatment with EGFRIs compromises skin barrier function and AMP production, leading to skin microbiota changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
- Multi-Omics for Functional Products in Food, Cosmetics and Animals Research Unit, Chulalongkorn University, Bangkok, Thailand.
- Division of Dermatology, Department of Medicine, Faculty of Medicine, Center of Excellence for Skin and Allergy Research, Chulalongkorn University, Bangkok, Thailand.
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Biostatistics Excellence Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence in Translational Research in Inflammation and Immunology, Chulalongkorn University, Bangkok, Thailand.
Zitieren
APA
Somboonna, N., Rujirawan, P., Promvaranon, T., Wongtada, C., Triwatcharikorn, J., Chottawornsak, N., Kantikosum, K., Wongsaroj, L., Parinyanitikul, N., Chongpison, Y., Chiewchengchol, D., & Rerknimitr, P. (2026). Skin Barrier Dysfunction, Antimicrobial Peptide Alterations, and Microbiome Changes in Solid Cancer Patients Treated with Epidermal Growth Factor Receptor Inhibitors. Dermatology, 242(4), 457-470. https://doi.org/10.1159/000551797
Vancouver
Somboonna N, Rujirawan P, Promvaranon T, Wongtada C, Triwatcharikorn J, Chottawornsak N, et al. Skin Barrier Dysfunction, Antimicrobial Peptide Alterations, and Microbiome Changes in Solid Cancer Patients Treated with Epidermal Growth Factor Receptor Inhibitors. Dermatology. 2026;242(4):457-470. doi:10.1159/000551797
BibTeX
@article{Somboonna2026,
author = {Somboonna, Naraporn and Rujirawan, Patcharapong and Promvaranon, Tiwanun and Wongtada, Chanidapa and Triwatcharikorn, Jidapa and Chottawornsak, Natcha and Kantikosum, Kornphaka and Wongsaroj, Lampet and Parinyanitikul, Napa and Chongpison, Yuda and Chiewchengchol, Direkrit and Rerknimitr, Pawinee},
title = {Skin Barrier Dysfunction, Antimicrobial Peptide Alterations, and Microbiome Changes in Solid Cancer Patients Treated with Epidermal Growth Factor Receptor Inhibitors},
journal = {Dermatology},
year = {2026},
volume = {242},
number = {4},
pages = {457--470},
doi = {10.1159/000551797}
}
EUVIMED